Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: BAllenP who wrote (1088)	7/23/1998 5:18:00 PM
From: Ariella	Respond to of 1491

S&P affirms its rating on BOL based, in part, because <<lRecent acquisitions of surgical businesses further diversify the company's operations within the ''eye care'' industry, and mark an aggressive entrance into the cataract and high growth eye surgery businesses. The acquisitions also enhance the appeal of the company's ophthalmic pharmaceuticals by strengthening Bausch & Lomb's relationship with ophthalmologists.>> biz.yahoo.com Encouraging news for our partner.... -Ariella